Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease

[1]  K. Lim,et al.  The Cast of Molecular Characters in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[2]  C. Shults.  Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[4]  Jeffrey H. Kordower,et al.  The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.

[5]  S. Hayashi,et al.  NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains , 2000, Acta Neuropathologica.

[6]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[7]  M. Graeber,et al.  Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease , 1998, Neurogenetics.

[8]  L. Moran,et al.  Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.

[9]  M. Smeyne,et al.  Glia cell number modulates sensitivity to MPTP in mice , 2005, Glia.

[10]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[11]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[12]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[13]  D. Botstein,et al.  Singular value decomposition for genome-wide expression data processing and modeling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Nakashima,et al.  p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells , 2004, Neuroscience Letters.

[15]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[16]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[17]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[18]  Bertrand Friguet,et al.  Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease , 2003, Journal of neurochemistry.

[19]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[20]  Y. Benjamini,et al.  On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics , 2000 .

[21]  N. Bresolin,et al.  Parkinson's Disease and Brain Mitochondrial Dysfunction: A Functional Phosphorus Magnetic Resonance Spectroscopy Study , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  Z. Makita,et al.  Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons , 2003, Brain Research.

[23]  G. Kolata.  Monkey model of Parkinson's disease. , 1983, Science.

[24]  G. Halliday,et al.  A possible role for humoral immunity in the pathogenesis of Parkinson's disease. , 2005, Brain : a journal of neurology.

[25]  W. Markesbery,et al.  Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Fletcher,et al.  Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease , 2002, Nature Genetics.

[27]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  J. Friedman.  Parkinson's disease update. , 1989, Rhode Island medicine.

[29]  H. Teräväinen,et al.  The Age of Onset of Parkinson's Disease: Etiological Implications , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[30]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[31]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[32]  Maria Speranza Desole,et al.  Hormones Are Key Actors in Gene X Environment Interactions Programming the Vulnerability to Parkinson's Disease: Glia as a Common Final Pathway , 2005, Annals of the New York Academy of Sciences.

[33]  A. Stromberg,et al.  Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: Statistical reliability and functional correlation , 2005, Ageing Research Reviews.

[34]  C. Tirolo,et al.  Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: Glia dictates resistance versus vulnerability to neurodegeneration , 2006, Neuroscience.

[35]  Jeffrey H Kordower,et al.  The role of alpha-synuclein in Parkinson's disease: insights from animal models. , 2003, Nature reviews. Neuroscience.

[36]  Reidun Torp,et al.  Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. , 2005, Human molecular genetics.

[37]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  C. Gustafsson,et al.  The mitochondrial RNA polymerase contributes critically to promoter specificity in mammalian cells , 2004, The EMBO journal.

[39]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[40]  D. Dickson,et al.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[41]  Jeffrey N Keller,et al.  Proteasome Inhibition Alters Neural Mitochondrial Homeostasis and Mitochondria Turnover* , 2004, Journal of Biological Chemistry.

[42]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[43]  The human genome: gene expression profiling and schizophrenia. , 2001, The American journal of psychiatry.

[44]  N. Wood.  Genes and parkinsonism. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[45]  B. Miller,et al.  Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration , 1998, Annals of neurology.

[46]  A. Singleton,et al.  Genes and parkinsonism , 2003, The Lancet Neurology.

[47]  W. Gibb.  Neuropathology of the substantia nigra. , 1991, European neurology.

[48]  N. Hattori,et al.  Familial Parkinson’s disease: a hint to elucidate the mechanisms of nigral degeneration , 2003, Journal of Neurology.

[49]  C. Olanow,et al.  Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.

[50]  S. Hayashi,et al.  NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. , 2000, Acta neuropathologica.

[51]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[52]  John Quackenbush.  Microarrays--Guilt by Association , 2003, Science.

[53]  Ash A. Alizadeh,et al.  'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns , 2000, Genome Biology.

[54]  C. Olanow,et al.  Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.

[55]  J. Bol,et al.  Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra , 2004, Neurobiology of Aging.

[56]  W. Gibb,et al.  The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. , 1990, Advances in neurology.

[57]  T. Peng,et al.  Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.

[58]  John Quackenbush.  Genomics. Microarrays--guilt by association. , 2003, Science.

[59]  Hitoshi Takahashi,et al.  Lewy bodies in Betz cells of the motor cortex in a patient with Parkinson's disease , 2003, Acta Neuropathologica.

[60]  M. Graeber,et al.  Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease , 1999, Neurogenetics.